Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY25 results · Jul–Sep 2024
Procter & Gamble Health reported revenue from operations of ₹313.41 crore (up 2.8% from Q2 FY24) and net profit of ₹82.33 crore (up 25.6% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 313.41 | 304.93 | +2.8% | 283.88 | +10.4% |
| Other income | 3.28 | 6.05 | −45.8% | 2.13 | +54.0% |
| Total income | 316.69 | 310.98 | +1.8% | 286.01 | +10.7% |
| Profit before tax | 111.40 | 88.05 | +26.5% | 22.83 | +388.0% |
| Net profit for the period | 82.33 | 65.57 | +25.6% | 16.78 | +390.6% |
| EPS, basic (₹) | 49.60 | 39.50 | +25.6% | 10.11 | +390.6% |
| Net margin (%) | 26.3 | 21.5 | 5.9 |
Standalone
- Filed with BSE
- 04 Nov 2024, 23:02 IST
- Board meeting
- 04 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE